The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial.
Administration, Oral
Adult
Blood Pressure
/ drug effects
Cannabinoid Receptor Agonists
/ pharmacology
Cross-Over Studies
Double-Blind Method
Dronabinol
/ pharmacology
Exercise
Female
Hemodynamics
Humans
Intraocular Pressure
/ drug effects
Laser-Doppler Flowmetry
Male
Optic Disk
/ blood supply
Regional Blood Flow
/ drug effects
Young Adult
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
07
10
2019
accepted:
04
01
2020
pubmed:
25
1
2020
medline:
17
2
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
It has been hypothesized that besides its intraocular pressure (IOP) lowering potential, tetrahydrocannabinol (THC) may also improve ocular hemodynamics. The aim of the present study was to investigate whether single oral administration of dronabinol, a synthetic THC, alters optic nerve head blood flow (ONHBF) and its regulation in healthy subjects. The study was carried out in a randomized, placebo-controlled, double-masked, two-way crossover design in 24 healthy subjects. For each study participant, 2 study days were scheduled, on which they either received capsules containing 5 mg dronabinol or placebo. ONHBF was measured with laser Doppler flowmetry at rest and while the study participants performed isometric exercise for 6 minutes to increase mean arterial blood pressure (MAP). This was repeated 1 hour after drug intake. Ocular perfusion pressure (OPP) was calculated as 2/3MAP-IOP. Dronabinol was well tolerated and no cannabinoid-related psychoactive effects were reported. Neither administration of dronabinol nor placebo had an effect on IOP, MAP, or OPP. In contrast, dronabinol significantly increased ONHBF at rest by 9.5 ± 8.1%, whereas placebo did not show a change in ONHBF (0.3 ± 7.4% vs. baseline, P < 0.001 between study days). Dronabinol did not alter the autoregulatory response of ONHBF to isometric exercise. In conclusion, the present data indicate that low-dose dronabinol increases ONHBF in healthy subjects without affecting IOP, OPP, or inducing psychoactive side effects. In addition, dronabinol does not alter the autoregulatory response of ONHBF to an experimental increase in OPP. Further studies are needed to investigate whether this effect can also be observed in patients with glaucoma.
Identifiants
pubmed: 31977076
doi: 10.1002/cpt.1797
pmc: PMC7325313
doi:
Substances chimiques
Cannabinoid Receptor Agonists
0
Dronabinol
7J8897W37S
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
155-161Informations de copyright
© 2020 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Curr Opin Pharmacol. 2013 Feb;13(1):36-42
pubmed: 23009741
PLoS One. 2013 Dec 06;8(12):e82351
pubmed: 24324774
Invest Ophthalmol Vis Sci. 2002 Mar;43(3):723-8
pubmed: 11867590
Exp Eye Res. 2015 Jul;136:45-58
pubmed: 25989217
Exp Eye Res. 1992 Sep;55(3):499-506
pubmed: 1426079
Acta Ophthalmol. 2010 Sep;88(6):622-9
pubmed: 19860779
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):4029-37
pubmed: 26098470
Br J Pharmacol. 2004 May;142(1):20-6
pubmed: 15131000
Curr Opin Ophthalmol. 2005 Apr;16(2):79-83
pubmed: 15744136
Pharmacology. 2007;79(1):12-6
pubmed: 17114903
Exp Eye Res. 2013 Nov;116:247-53
pubmed: 24060346
Invest Ophthalmol Vis Sci. 2003 Feb;44(2):728-33
pubmed: 12556405
Invest Ophthalmol Vis Sci. 2012 Jul 01;53(8):4337-46
pubmed: 22661477
FEBS J. 2013 May;280(9):1918-43
pubmed: 23551849
Br J Ophthalmol. 2004 May;88(5):708-13
pubmed: 15090428
Invest Ophthalmol Vis Sci. 2003 Feb;44(2):734-9
pubmed: 12556406
Invest Ophthalmol Vis Sci. 2000 Sep;41(10):3080-4
pubmed: 10967067
Am J Ophthalmol. 2007 Jan;143(1):173-4
pubmed: 17188063
Am J Physiol Heart Circ Physiol. 2013 Jan 1;304(1):H170-4
pubmed: 23103498
Exp Eye Res. 2018 Feb;167:145-151
pubmed: 29126840
Ophthalmology. 1980 Mar;87(3):222-8
pubmed: 7053160
Curr Neuropharmacol. 2018;16(7):959-970
pubmed: 28738764
Prog Retin Eye Res. 2008 Sep;27(5):501-26
pubmed: 18725316
Curr Opin Ophthalmol. 2009 Mar;20(2):73-8
pubmed: 19240538
Acta Ophthalmol. 2019 Feb;97(1):e36-e41
pubmed: 30218499
Invest Ophthalmol Vis Sci. 2013 Mar 15;54(3):1964-70
pubmed: 23439596
Exp Eye Res. 2011 Aug;93(2):141-55
pubmed: 20868686
J Cereb Blood Flow Metab. 2013 Dec;33(12):1850-6
pubmed: 23921903
Br J Pharmacol. 2003 Apr;138(7):1320-32
pubmed: 12711633
Br J Pharmacol. 2014 Mar;171(6):1361-78
pubmed: 24329566
J Glaucoma. 2006 Oct;15(5):349-53
pubmed: 16988594
JAMA. 1971 Sep 6;217(10):1392
pubmed: 5109652
Exp Eye Res. 1978 Jan;26(1):65-9
pubmed: 624325
Invest Ophthalmol Vis Sci. 2011 Sep 09;52(10):7068-73
pubmed: 21828157
Neural Plast. 2016;2016:9364091
pubmed: 26881140
PLoS One. 2017 Sep 12;12(9):e0184772
pubmed: 28898284
Prog Retin Eye Res. 2002 Jul;21(4):359-93
pubmed: 12150988
Can J Ophthalmol. 2008 Jun;43(3):317-21
pubmed: 18493273